Abstract 3887
Background
Tumour-tissue biopsy testing is the standard of care (SOC) to assess RAS mutation in mCRC pts. However, the analysis of circulating cell-free DNA (cfDNA) has the added advantage of being able to evidence genetic tumour heterogeneity. We explored the correlation of the RAS mutational status assessed in plasma samples with first-line (1L) treatment outcomes in SOC RAS wild type (wt) mCRC pts.
Methods
Prospective, observational, multi-centre study in mCRC pts with RASwt according to tumour-tissue biopsy and treated following standard clinical practice. Plasma samples were collected before starting 1L treatment and sent to Sysmex Inostics GmbH for BEAMing analysis. The lower threshold limit was a mutant allele fraction (MAF) ≥ 0.02%. Tumour response (TR) was evaluated approximately every 3 months based on RECIST criteria.
Results
119 pts were included (61% male; median age: 65 y). 113 received chemotherapy (CT) + anti-EGFR, 4 CT + anti-VEGF and 2 CT alone. Overall response rate (ORR) was 68.1% (95%CI: 58.9-76.3) for all pts and 75% (95%CI: 65.8-82.8) in the108 pts with TR data. In pts treated with panitumumab (n = 92), the most homogeneous group, 76.1% (n = 70) presented left-sided tumours and 19.6% (n = 18) right-sided; overall ORR was 78.3% (95%CI: 68.4-86.2); 81.4% (95%CI: 70.3-89.7) for left and 72.2% (95%CI: 46.5-90.3) for right-sided pts. ORR in the panitumumab subgroup according to RAS mutational status analysed in cfDNA for the three MAF (cut-offs) considered is presented in the table.Table: 546P
| ORR (not confirmed) % (95% CI) | ORR (not confirmed) % (95% CI) | Odds Ratio (95% CI); P-value* | |
|---|---|---|---|
| Mutant allele fraction, cut-off (n) | RASwt | RASmt | |
| ≥1% (90 wt/2 mt) | 78.9 (69.0 – 86.8) | 50.0 (1.3 - 98.7) | 3.7 (0.2 – 62.6) 0.389 |
| ≥0.1% (87 wt/5 mt) | 79.3 (69.3 – 87.3) | 60.0 (14.7 - 94.7) | 2.6 (0.4 – 16.5) 0.297 |
| ≥0.02% (80 wt/12 mt) | 80.0 (69.6- 88.1) | 66.7 (34.9-90.1) | 2.0 (0.5 – 7.5) 0.285 |
Fisher Test; CI=confidence interval; ORR: Overall Response Rate.
Conclusions
A high ORR was observed in pts treated with panitumumab independently of the localization. ORR in panitumumab treated patients tends to be higher in plasma RASwt. ORR in pts with plasma RASmt increases when a lower MAF cut-off is used. Further investigation is needed to find the optimal clinical cut-off. Study supported by Amgen.
Clinical trial identification
Legal entity responsible for the study
Amgen.
Funding
Amgen.
Editorial Acknowledgement
Disclosure
P. García Alfonso: Consulting fees: Amgen, Bristol, Merck, Sanofi, Roche, Bayer, Servier. M. Valladares-Ayerbes: Research grants: Roche; Consulting fees: Amgen, Roche, Merck, Sanofi, Servier. J.M. Viéitez: Research grants: Amgen, Roche; Consulting fees: Amgen, Roche, Servier, Shire, Bayer. J.J. Cruz Hernandez: Consulting fees: Amgen, Merck, Roche, BMS. A. Lloansí Vila: Full time employee, stocks: Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
4162 - ODM-207 - a novel BET bromodomain inhibitor with antitumor activity in nonclinical models of ER+ breast cancer
Presenter: Anu Moilanen
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3747 - HER2-positive breast cancer resistance to trastuzumab is associated with metabolic switch.
Presenter: Roman Dubianski
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4688 - Combination treatment with the PARP inhibitor niraparib and chemotherapeutics in a preclinical model of KRAS/BRAF mutated colorectal cancer cell lines across the four Consensus Molecular Subtypes.
Presenter: Pietro Paolo Vitiello
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
498 - Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway.
Presenter: Xiao Fu
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3731 - Effect of the polymorphism rs2470893 of the CYP1A1 gene on ovarian and endometrial cancer in Mediterranean women
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1215 - Cisplatin in NIPEC or HIPEC?
Presenter: Ivan Alvovsky
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2738 - Matrix metalloproteinase-mediated regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment
Presenter: MARIKO HIRAI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2190 - Trametinib synergizes with dexamethasone in KRAS-mutant myeloma cell lines through modulation of NDRG1 and induction of apoptosis
Presenter: Priya Sriskandarajah
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4482 - Functional inhibition of TGF-_ in colorectal cancer cells and its interaction with AXL receptor
Presenter: Davide Ciardiello
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
624 - Isoform-specific AKT Inhibition Differentially Affects Cell Functions in Pancreatic Adenocarcinoma
Presenter: Hugo Arasanz
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract